Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Kisspeptin-10

KP-10, Metastin (45-54), Kisspeptin-10 (human), KiSS-1

Quick Stats
Studies 877
Trials 47
Score 2
2007 pubmed

The role of gonadotropin releasing hormone in normal and pathologic endocrine processes.

Rothman. Micol S MS; Wierman. Margaret E ME

Key Findings

  • GnRH is the master hormone that drives pituitary gonadotropin release and reproductive function.
  • Kisspeptin signaling through its receptor is essential for activating GnRH neurons at puberty and can be disrupted by genetic mutations.
  • GnRH agonists and antagonists are clinically used for ovulation induction and long‑term prostate cancer therapy.

Practical Outcomes

  • Understanding the kisspeptin‑GnRH link helps biohackers grasp why certain fertility or hormone‑modulating supplements might work, but any use of GnRH analogs should be medically supervised. There are no actionable dosing recommendations for kisspeptin‑10 from this review, only insight into its role in normal and disease states.

Summary

This review explains how the brain hormone GnRH controls reproduction and how the kisspeptin pathway helps trigger GnRH release during puberty. It also covers how drugs that mimic or block GnRH are used to help women ovulate and to treat prostate cancer, and how genetic glitches in the kisspeptin or related pathways can cause delayed puberty. While it gives a clear picture of the biology, it doesn’t provide new dosing tips or DIY protocols for enthusiasts.

Abstract

Gonadotropin releasing hormone is the hypothalamic hormone that activates pituitary gonadotropin production and, ultimately, determines reproductive competence. This review will highlight advances in the basic biology of the gonadotropin releasing hormone neuron that give insight into disorders of pubertal development, and clinical studies with gonadotropin releasing hormone analogs in infertility and prostate cancer treatment. Factors that control gonadotropin releasing hormone neuronal migration such as fibroblast growth factor receptor-1 and others that modulate secretion at puberty including kisspeptin/G-protein-coupled receptor 54 have been identified. Mutations in these pathways cause disorders during puberty. Clinical trials have defined the utility of gonadotropin releasing hormone agonists and antagonists for ovulation induction, and the effects of long-term administration for prostate cancer. Research into the role of the fibroblast growth factor receptor-1 and kisspeptin/G-protein-coupled receptor 54 pathways in gonadotropin releasing hormone neuronal development may identify the molecular defects in idiopathic hypogonadotropic hypogonadism and refine our understanding of normal negative and positive feedback by sex steroids. Clarification of the advantages and disadvantages of gonadotropin releasing hormone analog use in ovulation induction may improve the cost and success of infertility treatment. Insight into long-term effects of gonadotropin releasing hormone analogs in prostate cancer may lead to directed therapies to combat these consequences. Together these studies outline effects of modulation of gonadotropin releasing hormone in normal and pathophysiologic states.

Study Information

Provider

pubmed

Year

2007

DOI

10.1097/med.0b013e3281e2c9fc